New study tracks Real-World effects of growth hormone drug in kids

NCT ID NCT05820672

Recruiting now Knowledge-focused Sponsor: Ascendis Pharma Endocrinology Division A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 900 children with growth hormone deficiency who are already taking SKYTROFA (lonapegsomatropin). Researchers will track side effects and measure how close children get to normal adult height. The goal is to see how well the drug works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKYTROFA (lonapegsomatropin)
What this could lead to: If successful, this study could confirm that SKYTROFA is safe and effective for helping children with growth hormone deficiency reach a normal adult height.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It is designed to gather real-world data, not to prove a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

isolated congenital growth hormone deficiency pituitary dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GROWTH HORMONE DEFICIENCY

Contacts and locations

Locations

Ascendis Investigational Site
RECRUITING

Phoenix, Arizona, 85054, United States
Ascendis Investigational Site
RECRUITING

Orange, California, 92868, United States
Ascendis Investigational Site
RECRUITING

Sacramento, California, 95821, United States
Ascendis Investigational Site
RECRUITING

San Francisco, California, 94143, United States
Ascendis Investigational Site
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Ascendis Investigational Site
RECRUITING

Orlando, Florida, 32806, United States
Ascendis Investigational Site
RECRUITING

Orlando, Florida, 32827, United States
Ascendis Investigational Site
RECRUITING

Tampa, Florida, 33612, United States
Ascendis Investigational Site
RECRUITING

Sandy Springs, Georgia, 30350, United States
Ascendis Investigational Site
RECRUITING

Boise, Idaho, 83712, United States
Ascendis Investigational Site
RECRUITING

Indianapolis, Indiana, 46202, United States
Ascendis Investigational Site
RECRUITING

Iowa City, Iowa, 52242, United States
Ascendis Investigational Site
RECRUITING

Louisville, Kentucky, 40202, United States
Ascendis Investigational Site
RECRUITING

Minneapolis, Minnesota, 55455, United States
Ascendis Investigational Site
RECRUITING

Las Vegas, Nevada, 89113, United States
Ascendis Investigational Site
RECRUITING

Lebanon, New Hampshire, 03756, United States
Ascendis Investigational Site
RECRUITING

Manchester, New Hampshire, 03104, United States
Ascendis Investigational Site
RECRUITING

Morristown, New Jersey, 07960, United States
Ascendis Investigational Site
RECRUITING

New Hyde Park, New York, 11042, United States
Ascendis Investigational Site
RECRUITING

Cincinnati, Ohio, 45229, United States
Ascendis Investigational Site
RECRUITING

Portland, Oregon, 97239, United States
Ascendis Investigational Site
RECRUITING

Columbia, South Carolina, 29203, United States
Ascendis Investigational Site
RECRUITING

Dallas, Texas, 75390, United States
Ascendis Investigational Site
RECRUITING

El Paso, Texas, 79907, United States
Ascendis Investigational Site
RECRUITING

Norfolk, Virginia, 23507, United States
Ascendis Investigational Site
RECRUITING

Seattle, Washington, 98105, United States
Ascendis Pharma Investigational Site
RECRUITING

Centennial, Colorado, 80112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.